RAPT Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300MB473BIU78ES48 - ISIN
US75382E1091 (RAPT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€96.43M - EBIT margin
0.0% - Net income
-€90.83M - Net margin
0.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
| N/A |
| |
| N/A |
| |
| N/A |
|
Dividends
No dividend payouts
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |